Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...
Get better recommendations Make better investments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback